Nishikori Momoko
Department of Hematology and Oncology, Kyoto University, Graduate School of Medicine.
Rinsho Ketsueki. 2019;60(9):1229-1235. doi: 10.11406/rinketsu.60.1229.
Recent advances in immunotherapy have highlighted the importance of the tumor microenvironment. Lymphomas are a heterogeneous group of malignancies that arise from lymphocytes and typically develop in lymphoid tissues. It has been recognized that the elements of the lymphoma microenvironment are not mere bystanders to a host antitumor inflammatory response but are important components of the tumor that support proliferation, survival, and chemoresistance of lymphoma cells. Lymphoma cells have individual expression patterns of chemokine receptors and adhesion molecules, according to their histological subtypes, and the patterns of surface molecules determine the sites of tumor involvement. Lymphoma cells often depend on the signals provided by non-tumor cells, such as stromal cells and macrophages, through direct cell contact and paracrine factors. On the other hand, there are genetic and non-genetic mechanisms allowing lymphoma cells to escape from anti-tumor immunity, such as downregulation of HLA molecules, B2M, CD58, CD70, and/or upregulation of PD-L1 and PD-L2. Further understanding of the interactions of lymphoma cells and the tumor microenvironment gives an insight into the pathogenesis of lymphomas and supports new approaches to their treatment.
免疫疗法的最新进展凸显了肿瘤微环境的重要性。淋巴瘤是一组异质性恶性肿瘤,起源于淋巴细胞,通常在淋巴组织中发生。人们已经认识到,淋巴瘤微环境的组成部分并非仅仅是宿主抗肿瘤炎症反应的旁观者,而是肿瘤的重要组成部分,支持淋巴瘤细胞的增殖、存活和化疗耐药性。淋巴瘤细胞根据其组织学亚型具有趋化因子受体和黏附分子的个体表达模式,而表面分子的模式决定了肿瘤累及的部位。淋巴瘤细胞通常依赖于非肿瘤细胞(如基质细胞和巨噬细胞)通过直接细胞接触和旁分泌因子提供的信号。另一方面,存在遗传和非遗传机制使淋巴瘤细胞逃避抗肿瘤免疫,如HLA分子、B2M、CD58、CD70的下调和/或PD-L1和PD-L2的上调。对淋巴瘤细胞与肿瘤微环境相互作用的进一步了解有助于深入了解淋巴瘤的发病机制,并支持其治疗的新方法。